Table 4.

Association between D-dimer cut-off of 1128 ng/mL and in-hospital mortality using logistic regression in the selected population of patients without censored outcome.

	Alive	In-hospital death	Univariate		Multivariable
			OR (95% CI)	P	OR (95% CI)	P
D-dimer > 1128 ng/mL	313 (40.9)	86 (71.1)	3.55 (2.35–5.45)	< 0.001	1.88 (1.08–3.30)	0.026
Age
50–60 years	157 (20.5)	7 (5.8)	1.23 (0.41–3.66)	0.71	1.07 (0.32–3.61)	0.91
60–70 years	168 (22.0)	19 (15.8)	3.12 (1.33–8.15)	0.012	1.03 (0.32–3.41)	0.95
70–80 years	133 (17.4)	25 (20.8)	5.18 (2.29–13.30)	< 0.001	4.47 (1.73–13.17)	0.003
80–90 years	86 (11.3)	40 (33.3)	12.82 (5.86–32.33)	< 0.001	9.70 (3.66–29.38)	< 0.001
90–110 years	27 (3.5)	22 (18.3)	22.47 (9.17–61.57)	< 0.001	18.04 (5.78–62.28)	< 0.001
Cancer
Cancer in remission	67 (8.8)	12 (9.9)	1.25 (0.62–2.31)	0.51	0.80 (0.32–1.84)	0.62
Active cancer	36 (4.7)	14 (11.6)	2.71 (1.37–5.11)	0.003	2.80 (1.06–6.99)	0.031
High blood pressure	333 (43.8)	80 (66.7)	2.56 (1.72–3.88)	< 0.001	0.92 (0.51–1.64)	0.77
Oral anticoagulation (NOAC or VKA)	64 (8.4)	23 (19.0)	2.56 (1.50–4.26)	< 0.001	1.46 (0.68–3.01)	0.32
Plasma creatinine (μmol/L)	86.6 (63.0)	139.2 (135.4)	1.01 (1.00–1.01)	< 0.001	1.01 (1.00–1.01)	< 0.001
Parenchymal opacification in chest CT scan > 50%	98 (15.0)	30 (32.6)	2.74 (1.67–4.42)	< 0.001	3.01 (1.64–5.49)	< 0.001
Venous thromboemboliceventa	43 (5.6)	5 (4.1)	0.72 (0.25–1.70)	0.50	1.05 (0.29–3.07)	0.93

Data are expressed as number (%) or mean ± standard deviation, unless otherwise indicated. CI: confidence interval; CT: computed tomography; NOAC: non-vitamin K antagonist oral anticoagulant; OR: odds ratio; VKA: vitamin K antagonist.

^aVenous thromboembolic event included deep vein thrombosis and pulmonary embolism.